New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Pitout, 2008, Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern, Lancet Infect Dis, 8, 159, 10.1016/S1473-3099(08)70041-0
WHO, 2014
Chang, 2011, Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study, J Microbiol Immunol Infect, 44, 125, 10.1016/j.jmii.2010.06.001
Falagas, 2014, Deaths attributable to carbapenem-resistant Enterobacteriaceae infections, Emerg Infect Dis, 20, 1170, 10.3201/eid2007.121004
Falagas, 2005, Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria, BMC Infect Dis, 5, 24, 10.1186/1471-2334-5-24
Sonnevend, 2017, Multi-hospital occurrence of pan-resistant Klebsiella pneumoniae ST147 with an ISEcp1-directed blaOXA-181 insertion into the mgrB gene in the United Arab Emirates, Antimicrob Agents Chemother, 61, 10.1128/AAC.00418-17
Weterings, 2015, An outbreak of colistin-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in the Netherlands (July to December 2013), with inter-institutional spread, Eur J Clin Microbiol Infect Dis, 34, 1647, 10.1007/s10096-015-2401-2
WHO, 2011
Rafailidis, 2014, Options for treating carbapenem-resistant Enterobacteriaceae, Curr Opin Infect Dis, 27, 479, 10.1097/QCO.0000000000000109
ClinicalTrials.gov Multicenter open-label randomized controlled trial (RCT) to compare colistin alone versus colistin plus meropenem. Available at: https://clinicaltrials.gov/ct2/show/NCT01732250; accessed February 2017.
Nation, 2016, Dosing guidance for intravenous colistin in critically ill patients, Clin Infect Dis, 62, 552, 10.1093/cid/civ964
Karageorgopoulos, 2012, Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases, J Antimicrob Chemother, 67, 2777, 10.1093/jac/dks270
Bush, 2017, What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles, J Pharmacokinet Pharmacodyn, 44, 113, 10.1007/s10928-017-9506-4
Sader, 2017, WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases, J Antimicrob Chemother, 72, 1696, 10.1093/jac/dkx050
Zhanel, 2013, Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination, Drugs, 73, 159, 10.1007/s40265-013-0013-7
Drawz, 2014, New β-lactamase inhibitors: a therapeutic renaissance in an MDR world, Antimicrob Agents Chemother, 58, 1835, 10.1128/AAC.00826-13
Ehmann, 2012, Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor, Proc Natl Acad Sci U S A, 109, 11663, 10.1073/pnas.1205073109
Bush, 2015, A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens, Int J Antimicrob Agents, 46, 483, 10.1016/j.ijantimicag.2015.08.011
Castanheira, 2015, Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains, Antimicrob Agents Chemother, 59, 3509, 10.1128/AAC.00163-15
Sader, 2015, Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011–2014), Diagn Microbiol Infect Dis, 83, 389, 10.1016/j.diagmicrobio.2015.06.008
Flamm, 2014, Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value, J Chemother, 26, 333
Walkty, 2011, In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study), Antimicrob Agents Chemother, 55, 2992, 10.1128/AAC.01696-10
Wang, 2014, In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China, Antimicrob Agents Chemother, 58, 1774, 10.1128/AAC.02123-13
Flamm, 2014, Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011), Diagn Microbiol Infect Dis, 80, 233, 10.1016/j.diagmicrobio.2014.07.005
Li, 2015, In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations, Antimicrob Agents Chemother, 59, 1789, 10.1128/AAC.04191-14
Vasoo, 2015, In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli, Antimicrob Agents Chemother, 59, 7842, 10.1128/AAC.02019-15
Humphries, 2015, First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate, Antimicrob Agents Chemother, 59, 6605, 10.1128/AAC.01165-15
Shields, 2015, Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae, Antimicrob Agents Chemother, 59, 5793, 10.1128/AAC.00548-15
Levasseur, 2012, In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates, Antimicrob Agents Chemother, 56, 1606, 10.1128/AAC.06064-11
Sader, 2015, Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013, Antimicrob Agents Chemother, 59, 3656, 10.1128/AAC.05024-14
Sader, 2015, Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia, Int J Antimicrob Agents, 46910, 53, 10.1016/j.ijantimicag.2015.02.022
Aktas, 2012, In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae, Int J Antimicrob Agents, 39, 86, 10.1016/j.ijantimicag.2011.09.012
Mazuski, 2016, Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program, Clin Infect Dis, 62, 1380, 10.1093/cid/ciw133
Wagenlehner, 2016, Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program, Clin Infect Dis, 63, 754, 10.1093/cid/ciw378
Shields, 2016, Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections, Clin Infect Dis, 63, 1615, 10.1093/cid/ciw636
Gallagher, 2016, Compassionate use of ceftazidime/avibactam (Cazavi) for carbapenem-resistant (Cr) Gram-negative rod infections. Abst 428. Abst ASM Microbe, Am Soc Microbiol
Temkin, 2017, Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms, Antimicrob Agents Chemother, 61, 10.1128/AAC.01964-16
Shields, 2017, Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia, Antimicrob Agents Chemother, 61, 10.1128/AAC.00883-17
Livermore, 2013, Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa, J Antimicrob Chemother, 68, 2286
Lapuebla, 2015, Activity of imipenem with relebactam against Gram-negative pathogens from New York City, Antimicrob Agents Chemother, 59, 5029, 10.1128/AAC.00830-15
Thaden, 2016, Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae, Virulence, 6, 1
Lucasti, 2016, Phase 2, Dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection, Antimicrob Agents Chemother, 60, 6234, 10.1128/AAC.00633-16
ClinicalTrials.gov. Imipenem/relebactam/cilastatin versus piperacillin/tazobactam for treatment of participants with bacterial pneumonia (MK-7655A-014) (RESTORE-IMI 2). Available at: https://clinicaltrials.gov/ct2/show/NCT02493764; accessed February 2017.
ClinicalTrials.gov. Efficacy and safety of imipenem+cilastatin/relebactam (mk-7655a) versus colistimethate sodium + imipenem+cilastatin in imipenem-resistant bacterial infection (MK-7655A-013) (RESTORE-IMI 1). Available at: https://clinicaltrials.gov/ct2/show/NCT02452047 accessed February 2017.
Hecker, 2015, Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class a serine carbapenemases, J Med Chem, 58, 3682, 10.1021/acs.jmedchem.5b00127
Lapuebla, 2015, Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City, Antimicrob Agents Chemother, 59, 4856, 10.1128/AAC.00843-15
Livermore, 2013, Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae, J Antimicrob Chemother, 68, 1825, 10.1093/jac/dkt118
Stus V, Sagan O, Bidair M, Loutit J, Dudley M et al. Meropenem-vaborbactam (M-V) versus piperacillin-tazobactam (P-T) in the treatment of adults with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP) in TANGO 1, a phase 3 randomized, double-blind, double-dummy trial. Presented at 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna April 2017.
ClinicalTrials.gov. Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults. Available at: https://clinicaltrials.gov/ct2/show/NCT02168946; accessed February 2017.
http://www.themedicinescompany.com/investors/news/medicines-company-announces-tango-2-trial-meropenem-vaborbactam-formerly-carbavance accessed August 2017.
Jacoby, 1996, Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli, J Clin Microbiol, 34, 908, 10.1128/JCM.34.4.908-911.1996
Yigit, 2003, Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2, Antimicrob Agents Chemother, 47, 3881, 10.1128/AAC.47.12.3881-3889.2003
Yoshizumi, 2015, In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations, J Infect Chemother, 21, 148, 10.1016/j.jiac.2014.08.028
Biedenbach, 2015, In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013, Antimicrob Agents Chemother, 59, 4239, 10.1128/AAC.00206-15
Kazmierczak, 2016, Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam, Antimicrob Agents Chemother, 60, 4490, 10.1128/AAC.00107-16
ClinicalTrials.gov. Determine the PK and safety and tolerability of ATM-AVI for the treatment of ciais in hospitalized adults (REJUVENATE). 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02655419; accessed February 2017.
Marshall, 2017, Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?, Antimicrob Agents Chemother, 61, 2243, 10.1128/AAC.02243-16
Davido, 2017, Ceftazidime-Avibactam and Aztreonam an interesting strategy to Overcome Β-lactam Resistance Conferred by Metallo-β-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa, Antimicrob Agents Chemother, 61, 10.1128/AAC.01008-17
Mojica, 2016, successful treatment of bloodstream infection due to metallo-β-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient, Antimicrob Agents Chemother, 60, 5130, 10.1128/AAC.00264-16
Zhanel, 2014, Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli, Drugs, 74, 31, 10.1007/s40265-013-0168-2
Takeda, 2007, In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa, Antimicrob Agents Chemother, 51, 826, 10.1128/AAC.00860-06
Cabot, 2014, Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC, Antimicrob Agents Chemother, 58, 3091, 10.1128/AAC.02462-13
Juan, 2010, Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains, Antimicrob Agents Chemother, 54, 846, 10.1128/AAC.00834-09
Sader, 2011, Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes, Antimicrob Agents Chemother, 55, 2390, 10.1128/AAC.01737-10
Sader, 2014, Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12), J Antimicrob Chemother, 69, 2713, 10.1093/jac/dku184
Pfaller, 2017, Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15), J Antimicrob Chemother, 72, 1386, 10.1093/jac/dkx009
Estabrook, 2014, In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases, J Clin Microbiol, 52, 4049, 10.1128/JCM.02357-14
Solomkin, 2015, Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI), Clin Infect Dis, 60, 1462, 10.1093/cid/civ097
Wagenlehner, 2015, Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI), Lancet, 385, 1949, 10.1016/S0140-6736(14)62220-0
Huntington, 2016, Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial, J Antimicrob Chemother, 71, 2014, 10.1093/jac/dkw053
Popejoy, 2017, Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials, J Antimicrob Chemother, 72, 268, 10.1093/jac/dkw374
ClinicalTrials.gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). Available at: www.clinicaltrials.gov/ ct2/show/NCT0207075; accessed February 2017.
Munita, 2017, Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa, Clin Infect Dis, 10.1093/cid/cix014
Page, 2010, In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli, Antimicrob Agents Chemother, 54, 2291, 10.1128/AAC.01525-09
Hofer, 2013, Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli, J Antimicrob Chemother, 68, 1120, 10.1093/jac/dks527
Mushtaq, 2013, Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters, J Antimicrob Chemother, 68, 1601, 10.1093/jac/dkt050
http://www.basilea.com/Portfolio/Portfolio/, accessed February 2017.
Mollmann, 2009, Siderophores as drug delivery agents: application of the “Trojan Horse” strategy, Biometals, 22, 615, 10.1007/s10534-009-9219-2
Ito, 2016, In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria, J Antimicrob Chemother, 71, 670, 10.1093/jac/dkv402
Kohira, 2016, In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains, Antimicrob Agents Chemother, 60, 729, 10.1128/AAC.01695-15
Ito-Horiyama, 2016, Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases, Antimicrob Agents Chemother, 60, 4384, 10.1128/AAC.03098-15
Portsmouth S, Vennhuyzen D, Echols R, Machida M, Ferrreira JCA, et al. Cefiderocol compared with imipenem/cilastatin in the treatment of adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis: results from a multicentre, double-blind, randomized study. Presented at 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna April 2017.
ClinicalTrials.gov. Study of S-649266 or best available therapy for the treatment of severe infections caused by carbapenem-resistant Gram-negative pathogens (CREDIBLE – CR). Available at: https://clinicaltrials.gov/ct2/show/NCT02714595?term=649266&rank=2; accessed February 2017.
Aggen, 2010, Synthesis and spectrum of the neoglycoside ACHN-490, Antimicrob Agents Chemother, 54, 4636, 10.1128/AAC.00572-10
Livermore, 2011, Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates, J Antimicrob Chemother, 66, 48, 10.1093/jac/dkq408
Galani, 2012, Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece, J Chemother, 24, 191
Almaghrabi, 2014, Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents, Antimicrob Agents Chemother, 58, 4443, 10.1128/AAC.00099-14
Walkty, 2014, In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011–2012, Antimicrob Agents Chemother, 58, 2554, 10.1128/AAC.02744-13
Garcia-Salguero, 2015, Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii?, Antimicrob Agents Chemother, 59, 5959, 10.1128/AAC.00873-15
http://www.achaogen.com/media-all/2012/5/15/achaogen-announces-all-objectives-met-in-phase-2-plazomicin-complicated-urinary-tract-infections-study-and-start-of-first-in-human-study-with-achn-975.
Cloutier D, Miller L, Komirenko A, Cebrik D, Krause et al. Plazomicin versus meropenem for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP): results of the EPIC study. Presented at 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna April 2017.
Connolly LE, Jubb AM, O’Keeffe B, Serio AW, Smith A, Gall J, et al. Plazomicin associated with improved survival and safety compared with colistin in serious carbapenem-resistant Enterobacteriaceae (CRE) infections: results of the CARE Study. Presented at ASM Microbe, New Orleans June 2017.
Zhanel, 2016, Review of eravacycline, a novel fluorocycline antibacterial agent, Drugs, 76, 567, 10.1007/s40265-016-0545-8
Bassetti, 2014, Eravacycline for the treatment of intra-abdominal infections, Expert Opin Investig Drugs, 23, 1575, 10.1517/13543784.2014.965253
Sutcliffe, 2013, Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens, Antimicrob Agents Chemother, 57, 5548, 10.1128/AAC.01288-13
Grossman, 2012, Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic, Antimicrob Agents Chemother, 56, 2559, 10.1128/AAC.06187-11
Abdallah, 2015, Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City, Antimicrob Agents Chemother, 59, 1802, 10.1128/AAC.04809-14
Zhang, 2016, In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline, J Antibiot (Tokyo), 69, 600, 10.1038/ja.2016.73
Livermore, 2016, In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii, Antimicrob Agents Chemother, 60, 3840, 10.1128/AAC.00436-16
Solomkin, 2016, Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial, JAMA Surg, 152, 224, 10.1001/jamasurg.2016.4237
Tetraphase announces top-line results from IGNITE2 phase 3 clinical trial of eravacycline in cuti. Available at: http://ir.tphase.com/releasedetail.cfm?releaseid=930613; accessed February 2017.
Prasad, 2012, Excess deaths associated with tigecycline after approval based on noninferiority trials, Clin Infect Dis, 54, 1699, 10.1093/cid/cis270
Shen, 2015, Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs, Int J Infect Dis, 39, 25, 10.1016/j.ijid.2015.08.009